Group 1 - Company Sanofi has entered into a collaboration with Pfizer for the 707 project, which involves a dual-targeting bispecific antibody product aimed at PD-1 and VEGF [1] - The collaboration allows Pfizer exclusive rights for development, production, and commercialization in regions outside mainland China [1] - The payment of sales milestone fees and royalties is contingent upon achieving specified sales targets, introducing uncertainty regarding actual revenue [1] Group 2 - Company Daqian Ecology announced that shareholders plan to reduce their holdings by up to 3.3% of the company's total shares [2] - Shareholder Anhui Xinhua Publishing Group intends to sell up to 407.16 million shares, while Vice General Manager Wang Zheng'an plans to sell up to 41.08 million shares [2] Group 3 - Company Sany Heavy Industry has submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange [3] - The application materials are in draft form and may be updated or revised as necessary [3] Group 4 - Company Xinhua Insurance plans to invest 10 billion yuan in the second phase of the Honghu Fund, which has a total size of 20 billion yuan [4] - The establishment of the fund is subject to regulatory procedures, introducing some uncertainty regarding its implementation [4] Group 5 - Company Zhongnan Media's subsidiary has signed a government procurement contract worth 1.009 billion yuan [6]

证券代码： 688336 证券简称：三生国健 公告编号：2025-024 三生国健药业（上海）股份有限公司 股票交易异常波动暨严重异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 三生国健药业（上海）股份有限公司（以下简称"公司"或"三 生国健"）股票交易连续两个交易日内（2025 年 5 月 21 日、2025 年 5 月 22 日）日收盘价格涨幅偏离值累计超过 30%，根据《上海证券交 易所交易规则》《上海证券交易所科创板股票异常交易实时监控细则》 的有关规定，属于股票交易异常波动情形。 公司股票交易连续四个交易日内（2025 年 5 月 19 日至 2025 年 5 月 22 日）日收盘价格涨幅偏离值累计超过 100%，根据《上海证 券交易所交易规则》《上海证券交易所科创板股票异常交易实时监控 细则》的有关规定，属于股票交易严重异常波动情形。 截至 2025 年 5 月 22 日，公司收盘价为 56.69 元/股，根据中 证指数有限公司发布的公司所处的生物药品行业最近一个月平均滚 动市盈率 ...

Core Viewpoint - Sangfor Biopharma (三生国健) has announced a collaboration with Pfizer for the development of project 707, a bispecific antibody targeting both PD-1 and VEGF, with potential uncertainties regarding milestone payments and royalties based on sales performance [1] Group 1 - Sangfor Biopharma's stock has experienced significant volatility, with a cumulative price deviation exceeding 30% over two trading days and 100% over four trading days, indicating abnormal trading activity [1] - The collaboration grants Pfizer exclusive rights to develop, produce, and commercialize the 707 project in regions outside mainland China for both human and veterinary applications [1] - The payment of milestone payments and royalties is contingent upon achieving specified sales targets, introducing uncertainty regarding the actual amounts received by the licensing parties [1] Group 2 - The sales performance of the licensed product may be influenced by various factors, including drug demand, market competition, and sales channels, contributing to the uncertainty surrounding the financial outcomes of the collaboration [1]

Group 1 - The core viewpoint of the article indicates that the company has a rolling price-to-earnings (P/E) ratio of 48.81, which is significantly higher than the industry average [1] - The company's stock has increased by over 100% since May 19, 2025, suggesting potential irrational speculation and a possible correction [1] - The company and its controlling shareholders do not have any undisclosed significant matters regarding the company, and its daily operations remain normal without major changes [1] Group 2 - There have been no significant adjustments in the industry policies affecting the company [1]

Market Overview - The Shanghai Composite Index fell by 0.22%, the Shenzhen Component Index decreased by 0.72%, and the ChiNext Index dropped by 0.96% on May 22, with a total market turnover of 1.1397 trillion yuan, a decrease of 74.6 billion yuan from the previous day [1] - Over 4,400 stocks closed in the red, while sectors such as military, banking, and gaming led the gains, whereas solid-state batteries and pet economy sectors saw declines [1] Stock Performance - A total of 40 stocks hit the daily limit up, with 13 stocks on consecutive limit up, and 27 stocks failed to close at the limit, resulting in a limit up rate of 60% (excluding ST and delisted stocks) [3] - Notable stocks included: - Sanofi's innovative drug concept stock, Sanofi Guojian, achieved a 20% limit up for four consecutive days [3] - Huibo Yuntong, involved in mergers and acquisitions, also reached a limit up for three consecutive days [3] Key Stocks and Transactions - Kunlun Wanwei saw a price increase of 20.01% to 37.43 yuan, with a turnover of 5.381 billion yuan and a turnover rate of 12.32% [4][5] - Zhongchao Holdings increased by 10.03% to 4.28 yuan, with a turnover of 744 million yuan and a turnover rate of 13.44% [12][13] - The top net purchases on the day were led by Kunlun Wanwei (339 million yuan), Zhongchao Holdings (210 million yuan), and Qingdao King (171 million yuan) [5] Institutional Activity - The top net selling stocks included Tianqimo (-2.83%), Hongbaoli (-8.60%), and Laisentongling (-10.02%) [6][20] - Institutional net purchases were significant in stocks like Kunlun Wanwei and Zhongchao Holdings, indicating strong interest from institutional investors [5][21] Sector Highlights - Kunlun Wanwei launched the "Skywork Super Agents," an AI agent architecture for multimodal content generation, which led to a surge in user engagement and subsequent stock performance [11] - Zhongchao Holdings is involved in military applications and low-altitude economy, with recent developments in high-temperature alloy precision casting for military aerospace components [14] - Zhongheng Electric, focusing on data center power and new power systems, reported a 111.05% increase in revenue from data center power business, contributing to overall revenue growth [19]

Core Viewpoint - Sanofi Health has reached a trading limit, with a transaction volume of 1.265 billion yuan and a turnover rate of 3.73% [1] Group 1 - The stock saw significant buying activity from the Shanghai-Hong Kong Stock Connect, with a net purchase of 72.1828 million yuan and a sale of 37.1571 million yuan [1] - Three institutional special seats recorded a net sell-off of 1.51 billion yuan [1] - There is an influx of dark pool funds into these stocks, indicating increased interest from institutional investors [1]

每日经济新闻 （责任编辑：张晓波 ） 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请 读者仅作参考，并请自行承担全部责任。邮箱：news_center@staff.hexun.com 5月22日，大盘弱势震荡，科创综指盘中翻红。截至 10:16，上证科创板综合指数上涨0.32%，成分股三生国健涨停，希荻微上涨14.10%，江苏北人上涨 8.48%，科捷智能上涨7.27%，国光电气上涨6.68%。科创综指ETF华夏(589000)上涨0.32%，最新价报0.94元。 流动性方面，科创综指ETF华夏盘中换手2.37%，交易较为活跃，成交6515.67万元。拉长时间看，截至5月21日，科创综指ETF华夏近1月日均成交1.75 亿元，居可比基金第一。资金流入方面，科创综指ETF华夏连续两日获资金净流入，最新资金净流入374.74万元。拉长时间看，近19个交易日内，合计"吸 金"2.39亿元。 消息方面，科创板融资余额较前一交易日增加2.79亿元，融券余额增加891.53万元。343股融资余额环比增加，123股融 ...

Group 1: Stock Performance - HaiTe GaoXin achieved a first board with a rise of 10.01% at 09:58, driven by military and nitrogen sectors [3] - SiChuang Electronics also saw a first board increase of 10.02% at 10:06, attributed to military and low economic factors [3] - FengHuo Electronics recorded a first board rise of 9.99% at 10:07, linked to military and low economic conditions [3] - GuoRui Technology had a first board increase of 10.00% at 10:08, focused on military applications [3] - GuoKe TianCheng experienced a significant first board rise of 20.00% at 10:25, related to military sectors [3] Group 2: Mergers and Acquisitions - ZongYi Co. has been on a 7-day streak with 6 boards, rising 10.06% at 09:41, due to merger and acquisition news [5] - BinHai Energy achieved a 4-day streak with 4 boards, increasing by 9.99% at 09:25, also linked to merger and acquisition activities [5] - HuiBo YunTong saw a 3-day streak with 3 boards, rising 20.00% at 09:25, attributed to merger and acquisition developments [5] - HongMing Co. had a first board increase of 20.00% at 09:39, driven by merger and acquisition news [5] Group 3: Technology and Innovation - Nanwei Semiconductor's stock surged over 195% after announcing a partnership with NVIDIA to develop next-generation 800V HVDC architecture [6] - ZhongHeng Electric achieved a first board rise of 9.99% at 09:30, linked to HVDC technology [7] - WanKong ZhiZao saw a first board increase of 9.97% at 09:46, associated with data center innovations [7] - HongBo Co. recorded a first board rise of 10.03% at 11:18, focused on computing power advancements [7] Group 4: Autonomous Driving - Baidu's autonomous driving platform, Luobo Kuaipao, now covers 15 cities with over 1000 unmanned vehicles, indicating significant growth in the sector [8] - TongDa Electric achieved a 2-day streak with 2 boards, rising 10.02% at 09:54, linked to ride-hailing services [9] - YaShi GuangDian had a first board increase of 9.99% at 09:40, attributed to developments in autonomous driving [9] Group 5: AI Applications - Kunlun Wanwei announced the global launch of the TianGong Super Intelligent Body, which utilizes AI agent architecture for content generation [10] - ShengShi Technology recorded a 4-day streak with 2 boards, rising 10.02% at 11:14, linked to computing power and AI [11] - Kunlun Wanwei saw an increase of 11.96%, driven by advancements in computing chips and intelligent systems [11] Group 6: Infrastructure and Transportation - The relationship between China and Indonesia is entering a new phase, with a focus on economic cooperation and major projects like the Jakarta-Bandung high-speed railway [14] - Shangwei Co. achieved a first board rise of 9.96% at 09:36, linked to nuclear power and high-speed rail developments [15] - Jinxi CheZhou recorded a first board increase of 10.00% at 09:43, associated with high-speed rail projects [15]

Group 1 - The innovative drug concept is gaining strength, with the Shanghai Stock Exchange Sci-Tech Innovation Board Biomedicine Index rising by 0.10% as of the report time, and stocks like Sanofi and others experiencing significant gains [1] - The Sci-Tech Innovation Medicine Index ETF (588700) is closely tracking the Biomedicine Index, showing a 0.20% increase and an active trading volume exceeding 15 million yuan, with a turnover rate of over 5.7% [1] - The Biomedicine Index reflects the overall performance of 50 major listed companies in the biomedicine sector on the Sci-Tech Innovation Board, covering various fields such as biomedicine, biomedical engineering, and biopharmaceuticals [1] Group 2 - Industry analysts predict a recovery in demand by 2025, with expectations of improvement in the consumption medical sector, including medical services and traditional Chinese medicine OTC products [2] - The medical device sector is also anticipated to see improvements by 2025, alongside the emergence of AI in healthcare, which is expected to bring significant changes to the pharmaceutical industry [2] - The pharmaceutical sector is believed to have completed the transition between old and new growth drivers, with enhanced capabilities for innovation and international expansion [2]

Group 1 - The core point of the news is that the company Sanofi Guojian has signed a licensing agreement with Pfizer for the exclusive development, production, and commercialization of the 707 project, which targets both PD-1 and VEGF [1] - Pfizer will pay an upfront fee of $1.25 billion, which sets a new record for upfront payments for domestic innovative drugs going abroad, and the total potential payments could reach up to $4.8 billion [1] - The agreement signifies recognition of the R&D capabilities of domestic innovative drug companies by top international pharmaceutical firms, marking a milestone for domestic pharmaceutical companies in entering the global market [1] Group 2 - The 707 project is a bispecific antibody product that requires internal decision-making processes and regulatory approvals before implementation, indicating some uncertainty in the execution [1] - The domestic pharmaceutical industry has seen significant growth in recent years, supported by domestic pharmaceutical policies and capital market financing policies for innovative drug R&D [1] - Over 25 domestic Class 1 innovative drugs have been approved for listing on the Sci-Tech Innovation Board, and more than 10 innovative drug companies have granted overseas rights to foreign companies through licensing agreements [2]